CD274 and non-small cell lung carcinoma: Recent approvals in the non-metastatic setting include the use of (neo)adjuvant ICIs with chemotherapy for patients with resectable NSCLC with a high risk of recurrence and programmed death ligand 1 (PD-L1) expression ≥ 1%, and the use of adjuvant ICIs with chemotherapy in patients with stage II–IIIA NSCLC and a high risk of recurrence plus PD-L1 expression ≥ 50% is a further example of how the treatment landscape is evolving with great potential for improved outcomes in patients [38,39,40].